Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury.
Koyner JL
,
Chawla LS
,
Bihorac A
,
Gunnerson KJ
,
Schroeder R
,
Demirjian S
,
Hodgson L
,
Frey JA
,
Wilber ST
,
Kampf JP
,
Kwan T
,
McPherson P
,
Kellum JA
,
RUBY investigators
.
???displayArticle.abstract???
BACKGROUND: Clinical use of biomarkers requires the development of standardized assays and establishment of cutoffs. Urinary C-C motif chemokine ligand 14 (CCL14) has been validated to predict persistent severe AKI in critically ill patients with established AKI. We now report on the performance of standardized cutoffs using a clinical assay.
METHODS: A second aim of the multicenter RUBY Study was to establish two cutoffs for the prediction of persistent severe AKI (defined as KDIGO stage 3 AKI for at least 72 consecutive hours). Patients who received renal replacement therapy (RRT) or died before achieving 72 hours in stage 3 AKI were also considered to have reached the end point.
RESULTS: A cutoff value for urinary CCL14 of 1.3 ng/ml was determined to achieve high sensitivity (91%; 95% CI, 84% to 96%), and 13 ng/ml achieved high specificity (93%; 95% CI, 89% to 96%). The cutoff of 1.3 ng/ml identifies the majority (91%) of patients who developed persistent severe AKI with a negative predictive value of 92%. The cutoff at 13 ng/ml had a positive predictive value of 72% (with a negative predictive value of 75%). In multivariable adjusted analyses, a CCL14 concentration between 1.3 and 13 ng/ml had an adjusted odds ratio (aOR) of 3.82 (95% CI, 1.73 to 9.12; P=0.001) for the development of persistent severe AKI compared with those with a CCL14 ≤1.3 ng/ml, whereas a CCL14 >13 ng/ml had an aOR of 10.4 (95% CI, 3.89 to 29.9; P<0.001).
CONCLUSIONS: Using a clinical assay, these standardized cutoffs (1.3 and 13 ng/ml) allow for the identification of patients at high risk for the development of persistent severe AKI. These results have immediate utility in helping to guide AKI patient care and may facilitate future clinical trials.Clinical Trial registry name and registration number: Identification and Validation of Biomarkers of Acute Kidney Injury Recovery, NCT01868724.
Bagshaw,
External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury.
2021, Pubmed
Bagshaw,
External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury.
2021,
Pubmed
Bagshaw,
Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.
2020,
Pubmed
Barbar,
Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.
2018,
Pubmed
Chertow,
Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.
2005,
Pubmed
Chindarkar,
Reference intervals of urinary acute kidney injury (AKI) markers [IGFBP7]∙[TIMP2] in apparently healthy subjects and chronic comorbid subjects without AKI.
2016,
Pubmed
Churpek,
Internal and External Validation of a Machine Learning Risk Score for Acute Kidney Injury.
2020,
Pubmed
Coca,
First Post-Operative Urinary Kidney Injury Biomarkers and Association with the Duration of AKI in the TRIBE-AKI Cohort.
2016,
Pubmed
Cruz,
Use of biomarkers to assess prognosis and guide management of patients with acute kidney injury.
2013,
Pubmed
Detheux,
Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties.
2000,
Pubmed
Feinstein,
The inadequacy of binary models for the clinical reality of three-zone diagnostic decisions.
1990,
Pubmed
Gaudry,
Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.
2016,
Pubmed
Hobson,
Cost and Mortality Associated With Postoperative Acute Kidney Injury.
2015,
Pubmed
Hodgson,
Correction: The ICE-AKI study: Impact analysis of a Clinical prediction rule and Electronic AKI alert in general medical patients.
2018,
Pubmed
Hoste,
Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study.
2020,
Pubmed
Hsu,
Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study.
2020,
Pubmed
Keller,
Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction.
2011,
Pubmed
Kellum,
Recovery after Acute Kidney Injury.
2017,
Pubmed
Küllmar,
A Multinational Observational Study Exploring Adherence With the Kidney Disease: Improving Global Outcomes Recommendations for Prevention of Acute Kidney Injury After Cardiac Surgery.
2020,
Pubmed
Maisel,
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.
2002,
Pubmed
Massoth,
Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery.
2023,
Pubmed
Md Dom,
Effect of TNFα stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia.
2021,
Pubmed
Meersch,
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial.
2017,
Pubmed
Mehta,
The prognostic importance of duration of AKI: a systematic review and meta-analysis.
2018,
Pubmed
Moledina,
Variation in Best Practice Measures in Patients With Severe Hospital-Acquired Acute Kidney Injury: A Multicenter Study.
2021,
Pubmed
Mutter,
Electronic Alerts for Acute Kidney Injury Amelioration (ELAIA-1): a completely electronic, multicentre, randomised controlled trial: design and rationale.
2019,
Pubmed
Ozrazgat-Baslanti,
Clinical Trajectories of Acute Kidney Injury in Surgical Sepsis: A Prospective Observational Study.
2022,
Pubmed
Peerapornratana,
Sepsis-Associated Acute Kidney Disease.
2020,
Pubmed
Ronco,
Acute kidney injury.
2019,
Pubmed
Selby,
An Organizational-Level Program of Intervention for AKI: A Pragmatic Stepped Wedge Cluster Randomized Trial.
2019,
Pubmed
Vyshkina,
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.
2008,
Pubmed
Wald,
Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.
2015,
Pubmed
Zarbock,
Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial.
2021,
Pubmed